ADX71149 (mGlu2 PAM) for the treatment of epilepsy.
Our partnered drug candidate, ADX71149 is a novel orally active metabotropic glutamate receptor subtype 2, or mGlu2 PAM.
Our partner, Janssen, has completed Phase 1 and two Phase 2a clinical trials in schizophrenia and anxious depression, respectively, and is planning to advance into a Phase 2a proof of concept study in patients with epilepsy. The multi-center study is scheduled to begin dosing patients in the United States early in 2021.
Under our agreement with Janssen, Janssen is responsible for financing the development and commercialization, if any, of ADX71149.